Q3 2019

Filed Nov 13, 2019 · 10-Q · 44 days after period end · 0001213900-19-023117

Q3 2019 · 10-Q

Revenue—

Net Income

-$874.12K

N/M vs Q3 2018

EPS Diluted

-$0.01

— vs Q3 2018

Operating Income-$850,319N/M

Operating Cash Flowderived-$32,053N/M

Same quarter

Metric	Q3 2019	Q3 2018	Q3 2017	Q3 2016
Revenue	—	—	$111.98K	$101.14K
Net Income	-$874.12K	-$47.52K	$48.88K	-$213.99K
EPS Diluted	-$0.01	$0.00	$0.00	-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR